Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GW Pharmaceuticals identifies novel oral cannabinoid candidate for type 2 diabetes

Nov. 29, 2012

EMA recommends granting orphan status to Aspireo's somatoprim

Nov. 26, 2012

Arena Pharmaceuticals divulges novel GRP119 receptor agonists

Nov. 26, 2012

Study of alpha-1-antitrypsin drug shows efficacy and safety in type 1 diabetes

Nov. 23, 2012

GSK-1292263 markedly reduces lipids in nondiabetic subjects

Nov. 23, 2012

Niacin analogue ARI-3037-MO evaluated in healthy subjects

Nov. 23, 2012

Researchers at Pfizer present new acetyl-CoA carboxylase inhibitors

Nov. 22, 2012

Scientists at Daiichi Sankyo prepare new 11-beta-HSD1 inhibitors

Nov. 22, 2012

Antisense oligonucleotide drug targets alpha-1-antitrypsin deficiency

Nov. 22, 2012

EMA committee recommends approval of lixisenatide

Nov. 19, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...